---
title: "Checkpoint Therap (CKPT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CKPT.US.md"
symbol: "CKPT.US"
name: "Checkpoint Therap"
industry: "生物技術"
---

# Checkpoint Therap (CKPT.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |

## Company Profile

Checkpoint Therapeutics, Inc.是一家商業階段的免疫療法和靶向腫瘤學公司，專注于在美國和國際上獲取、開發和商業化針對實體腫瘤癌症患者的新型治療方案。該公司的主要抗體產品候選藥物是 UNLOXCYT，目前正在進行針對特定复發性或轉移性癌症患者的第一階段臨床試驗；CK-302 則是一個正在進行血液惡性腫瘤和實體腫瘤的臨床前試驗的產品候選藥物。公司還在開發 Olafertinib，該藥物正在進行針對轉移性非小細胞肺癌成年患者的第三階段臨床試驗；CK-103 用于治療各種晚期和轉移性實體腫瘤癌症；以及抗碳酸酐酶 IX（CAIX）抗體，這是一個正在進行臨床前試驗的產品候選藥物，...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:15.000Z

**Overall: D (0.79)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 365 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -39.71% |  |
| Net Profit YoY | -8.01% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 41000.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1869.55% | E |
| Profit Margin | -137821.95% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -39.71% | E |
| Net Profit YoY | -8.01% | C |
| Total Assets YoY | 185.29% | A |
| Net Assets YoY | 258.98% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.07% | D |
| OCF YoY | -39.71% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 52.30% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Checkpoint Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1869.55%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-137821.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-39.71%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-8.01%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "185.29%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "258.98%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.07%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-39.71%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "52.30%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.31 | 491/603 | - | - | - |
| PB | 21.90 | 468/603 | 21.90 | 21.90 | 21.90 |
| PS (TTM) | 8703.26 | 350/603 | 8703.26 | 8703.26 | 8417.23 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.26 |
| Highest Target | 4.80 |
| Lowest Target | 4.10 |

## References

- [Company Overview](https://longbridge.com/en/quote/CKPT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CKPT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CKPT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.